statistiche ricercatore

statistiche per De Luca, Andrea

Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4859
NA - Nord America 3273
AS - Asia 1397
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 4
SA - Sud America 4
Totale 9563
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3231
DE - Germania 1684
CN - Cina 1125
UA - Ucraina 886
PL - Polonia 664
FR - Francia 581
IT - Italia 399
FI - Finlandia 209
SE - Svezia 196
GB - Regno Unito 171
IN - India 136
TR - Turchia 81
RU - Federazione Russa 29
CA - Canada 23
JP - Giappone 20
NL - Olanda 14
BZ - Belize 11
IR - Iran 11
CM - Camerun 8
MX - Messico 8
EU - Europa 7
KR - Corea 6
CH - Svizzera 5
HK - Hong Kong 5
VN - Vietnam 5
RO - Romania 4
AU - Australia 3
GR - Grecia 3
IE - Irlanda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BR - Brasile 2
EG - Egitto 2
ES - Italia 2
KE - Kenya 2
PH - Filippine 2
SG - Singapore 2
TW - Taiwan 2
UG - Uganda 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BY - Bielorussia 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
IS - Islanda 1
LK - Sri Lanka 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
ZA - Sudafrica 1
Totale 9563
Salva come PNG Salva come JPEG
Città #
Jacksonville 569
Kraków 520
San Mateo 406
Dearborn 287
Nanjing 275
Wilmington 181
Houston 166
Ann Arbor 165
Beijing 155
Cattolica 151
Redmond 143
Warsaw 142
Hangzhou 136
Woodbridge 132
Ashburn 110
Nürnberg 106
Nanchang 102
Seattle 96
Redwood City 91
Izmir 78
Lancaster 73
Mountain View 65
University Park 64
Shenyang 58
Fairfield 52
Milan 50
Kunming 48
Hebei 43
Changsha 40
Guangzhou 36
Fremont 34
Jiaxing 33
Falls Church 28
Munich 28
Tianjin 28
Jinan 27
Norwalk 27
Verona 24
San Jose 23
Cambridge 22
Hefei 20
Zhengzhou 20
Scottsdale 19
Shanghai 19
Simi Valley 19
Chicago 16
Rome 16
Indiana 14
Ottawa 14
Augusta 12
Detroit 12
Fuzhou 12
Leawood 12
Belize City 11
Buffalo 8
Changchun 8
Wenzhou 8
Albuquerque 7
Auburn Hills 7
Lanzhou 7
Las Vegas 7
New York 7
Philadelphia 7
Saarbrücken 6
San Francisco 6
Helsinki 5
Kish 5
Carate Brianza 4
Central District 4
Chongqing 4
Costa Mesa 4
Hanoi 4
Montréal 4
Napoli 4
Ningbo 4
Wuhan 4
Andover 3
Baotou 3
Capelle 3
Clearwater 3
Cuauhtémoc 3
Mcallen 3
Omsk 3
Phoenix 3
Siena 3
Southend 3
Taizhou 3
Toronto 3
Ardabil 2
Barcelona 2
Cameri 2
Chapar 2
Chengdu 2
Cupertino 2
Fabriano 2
Faenza 2
Henderson 2
Kocaeli 2
Latina 2
Lequile 2
Totale 5214
Salva come PNG Salva come JPEG
Nome #
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. 285
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 237
Common genetic variation and the control of HIV-1 in humans. 186
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 169
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 161
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 133
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 126
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 123
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 118
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 109
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 105
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 96
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 94
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study 90
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 87
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 87
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 84
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 78
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 77
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 76
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 73
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 72
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 71
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 71
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 70
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 69
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 67
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 64
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 63
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy 63
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 63
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120 62
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop 62
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 61
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 61
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 60
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study 60
Evolution and predictors of HIV type 1 drug resistance in patients failing combination antiretroviral therapy in Italy 60
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 60
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 60
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? 59
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 59
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 59
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 58
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. 58
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 56
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 55
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 55
Hyperbilirubinemia during atazanavir treatment in 2404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 55
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 55
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 55
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 55
Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania 54
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 52
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 52
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 52
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 52
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 51
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 51
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 51
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 51
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). 50
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 50
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 50
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 50
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 49
Phemphigus vulgaris in a human-immunodeficiency-virus-infected patient. 49
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 48
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 48
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 48
An outbreak of HIV-1 subtype G among Italian injecting drug users 47
Lipid-lowering effect of tenofovir in HIV-infected patients 47
Interpretation systems for genotypic drug resistance of HIV-1 47
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 47
Incidence and Predictors of Death, Retention, and Switch to Second-Line Regimens in Antiretroviral-Treated Patients in Sub-Saharan African Sites with Comprehensive Monitoring Availability 46
Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries 46
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation. 45
Long term follow-up of Nevirapine-treated patients in a single centre cohort 45
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 45
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 45
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 44
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 43
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 43
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 43
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 42
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 42
Clinical implications of HIV-1 drug resistance in the neurological compartment 42
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 42
Italian consensus statement on management of HIV-infected individualswith advanced disease naive to antiretroviral therapy 41
A novel methodology for large-scale phylogeny partition 41
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 41
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 40
Decline of CD4 T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals 40
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group 40
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 40
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 40
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 39
Impairment of recent thymic emigrants in HCV infection. 38
Risk of developing specific AIDS-defining illnesses in patients coinefcted with HIV and hepatitis C virus with or without liver cirrhosis 38
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years 38
Totale 6677
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9744
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9744
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2016/2017249 0000 00 00 0019554
2017/20181441 604595409 12559 71176 14231122106
2018/20191360 486841166 252206 19142 447215179
2019/20202285 45823312287 183291 15294 116132188229
2020/20211750 13420745199 21599 19131 2723828039
2021/20221325 1851984394 6881 31315 701371030
Totale 9744
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie-Privacy
Logo CINECA  Copyright © 2022